Strategies for the design of novel thrombolytic and antithrombolytic agents.
Recent advances in our understanding of thrombosis and thrombolysis have led to the design of new thrombolytic agents and regimens that may offer improved efficacy. In general, these new approaches specifically target pivotal steps in thrombus formation or lysis. The goal is to reduce adverse side effects (such as bleeding complications) that result from development of a lytic state or that result from a failure to maintain patency (as characterized by rethrombosis). The points in the coagulation cascade that are susceptible to inhibition, as well as the proposed agents for intervention, are discussed in this review.
Division of Cardiology, Emory University School of Medicine, Atlanta, GA 30322, USA.
I M
IM
Lubin
D J
DJ
Hayzer
M S
MS
Runge